# A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

> **NCT06694805** · PHASE3 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 332 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CAB LA + RPV LA
- **DRUG:** Oral ART

## Key facts

- **NCT ID:** NCT06694805
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2026-08-19
- **Final completion:** 2028-07-19
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694805, "A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06694805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*